Shilpa Medicare Ltd (SHILPAMED) — shareholding pattern, promoter holding, financials and share price
About Shilpa Medicare Ltd (SHILPAMED)
Shilpa Medicare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SHILPAMED and on the BSE under scrip code 530549. Its ISIN is INE790G01031.
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics. [1]
Shilpa Medicare Limited is an Indian pharmaceutical company specializing in APIs, formulations, and biologics, with a global presence in over 50 countries.
In 3Q FY26, Shilpa achieved its highest quarterly revenue of INR 411 crores, marking a 28% growth YoY, driven by significant advances in the formulation and biologics segments.
Listed peers in Pharmaceuticals: Concord Biotech Ltd, Corona Remedies Ltd, Marksans Pharma Ltd, Viyash Scientific Ltd, Procter & Gamble Health Ltd, Akums Drugs & Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹627 a share on 10 Jul 2026, Shilpa Medicare Ltd (SHILPAMED) was valued at a price-to-earnings ratio of 50.4x against an industry P/E of 36.41x and a price-to-book of 5.17x on a book value of ₹121.29 per share as of Mar 2025. Solomo computes return on equity of 10.26% and return on capital employed of 11.96% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 50.4x
- Industry P/E
- 36.41x
- P/B
- 5.17x
- EPS (TTM)
- ₹12.44
- Book value / share
- ₹121.29
- ROE
- 10.26%
- ROCE
- 11.96%
- ROA
- 7.35%
- Debt / equity
- 0.25x
- Dividend yield
- 0.16%
- EBITDA margin
- 30.79%
- 52-week range
- ₹260 – ₹633.6
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Shilpa Medicare Ltd (SHILPAMED) reported revenue of ₹1,539 crore, net profit of ₹243 crore and earnings per share of ₹12.44. That compares with revenue of ₹1,281 crore and net profit of ₹78 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹437 crore and net profit ₹108 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,141 | 1,046 | 1,146 | 1,281 | 1,539 |
| Net profit (₹ cr) | 61 | -31 | 32 | 78 | 243 |
| EPS (₹) | 3.49 | -1.87 | 1.84 | 4 | 12.44 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -3.88% | -9.95% | 10.17% | 11.71% |
| Profit growth | -5.20% | -16.13% | 51.29% | 144.99% |
| Stock price CAGR | 8% | 16% | 59% | 37% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 40.13% of Shilpa Medicare Ltd (SHILPAMED) (unchanged from the previous quarter), foreign institutional investors (FII) hold 11.38% and domestic institutional investors (DII) hold 8.05%. Promoters have pledged 8.7% of their holding. Market capitalisation was ₹12,263 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: SURAJ KUMAR INANI 4.01%, SBI LIFE INSURANCE CO. LTD 2.31%, SUNIDHI CAPITAL PRIVATE LIMITED 2.25%, COHESION MK BEST IDEAS SUB-TRUST 2.17%, AMAL PARIKH 1.73%, DOVETAIL INDIA FUND CLASS 5 SHARES 1.71%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 40.13% | 8.7% | 11.38% | 8.05% | 59.87% |
| Mar 2026 | 40.13% | 8.7% | 11.08% | 8.58% | 59.87% |
| Dec 2025 | 40.13% | 8.7% | 10.97% | 8.33% | 59.87% |
| Sep 2025 | 44.23% | 7.9% | 10.92% | 7.67% | 55.77% |
| Jun 2025 | 44.23% | 7.9% | 11.2% | 7.46% | 55.77% |
| Mar 2025 | 44.23% | 7.9% | 10.97% | 7.55% | 55.77% |
| Dec 2024 | 44.23% | 7.9% | 9.9% | 8.27% | 55.77% |
| Sep 2024 | 44.33% | 7.9% | 9.58% | 8.18% | 55.67% |